574745-76-9

Basic information

• Product Name: 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-ol
• Synonyms: 4-[(4-fluoro-2-methyl-1H-indol-5-yloxy)]-6-methoxy-7-Quinazolinol;4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-ol;7-Quinazolinol, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-
• CAS NO: 574745-76-9
• Molecular Formula: C₁₈H₁₄FN₃O₃
• Molecular Weight: 339.325
• Mol File: 574745-76-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 553.714 °C at 760 mmHg
• Flash Point: 288.676 °C
• Appearance: /
• Density: 1.438
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.712
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-ol(574745-76-9)
• EPA Substance Registry System: 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-ol(574745-76-9)

Safety Data

• Hazardous Substances Data: 574745-76-9(Hazardous Substances Data)

Usage

General Description

The chemical 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-ol, also known as AG1478, is a synthetic compound that belongs to the quinazoline family. It is a specific inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which plays a key role in cell growth and division. By blocking the activity of EGFR, AG1478 has the potential to suppress the proliferation of cancer cells, making it a promising candidate for anticancer drug development. Its specific structure and mode of action make it a valuable tool for studying the biology of EGFR and for understanding the molecular mechanisms involved in cancer progression.

InChI:InChI=1/C18H14FN3O3/c1-9-5-10-12(22-9)3-4-15(17(10)19)25-18-11-6-16(24-2)14(23)7-13(11)20-8-21-18/h3-8,22-23H,1-2H3

Upstream product

• 162364-72-9 7-benzyloxy-4-chloro-6-methoxyquinazoline 
• 288385-88-6 4-fluoro-2-methyl-1H-indol-5-ol 
• 1022112-47-5 1-(3-{[7-(benzyloxy)-6-methoxyquinazolin-4-yl]oxy}-2-fluoro-6-nitrophenyl)acetone 
• 574745-75-8 7-(benzyloxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)-oxy]-6-methoxyquinazoline 

Downstream Products

• 288383-20-0 cediranib 

Relevant articles and documents

Angiogenesis inhibitor as well as preparation method and application thereof

The invention belongs to the technical field of medicines, and discloses a compound shown as a formula I or pharmaceutically acceptable salt, prodrug, metabolite, isotope derivative and solvate thereof. The compound provided by the invention is a cyclobutyl-containing compound used as a tyrosine kinase inhibitor, and can be used for treating tyrosine kinase, especially tumor diseases related to VEGFR. Due to the existence of the cyclobutyl group, the rigidity of a branched chain molecule can be improved, the directivity of the molecule is improved, the compound can be better combined with a target easily, the dosage of a drug can be reduced, and the side effect of the drug is reduced. The invention also provides a preparation method of the compound and application of the compound in treatment of tumor diseases caused by abnormal activity of tyrosine kinase such as VEGFR.

west Neeb salt and its crystalline form, and its preparation method and pharmaceutical composition (by machine translation)

The invention relates to west Neeb salt and its crystalline form, compared with the prior art, and its west Neeb salt of the invention the crystalline form has more excellent in water solubility. The present invention also relates to the west states the Neeb salt and its crystal preparation method, the medicament composition and its use in treating and/or preventing the pathological angiogenic diseases use of the medicament. (by machine translation)

VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to VEGFR inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.